loading page

Production of MSTN mutated cattle using CRISPR--Cas9
  • +9
  • Gyeong-Mim Gim,
  • Dong-Hyuk Kwon,
  • Kyeong-Hyeon Eom,
  • Joon-Ho Moon,
  • Ji-Hyun Park,
  • Dae-Jin Jung,
  • Dae-Hyun Kim,
  • Jun-Koo Yi,
  • Jae-Jung Ha,
  • Ka-Yeong Lim,
  • Jin Su Kim,
  • Goo Jang
Gyeong-Mim Gim

Corresponding Author:tty4447@naver.com

Author Profile
Dong-Hyuk Kwon
Author Profile
Kyeong-Hyeon Eom
Author Profile
Joon-Ho Moon
Author Profile
Ji-Hyun Park
Author Profile
Dae-Jin Jung
Author Profile
Dae-Hyun Kim
Author Profile
Jun-Koo Yi
Author Profile
Jae-Jung Ha
Author Profile
Ka-Yeong Lim
Author Profile
Jin Su Kim
Author Profile
Goo Jang
Seoul National University
Author Profile

Abstract

Many transgenic animals have been produced using CRISPR–Cas9 technology to edit specific genes. However, there are few guidelines for the application of this technique in cattle. The goal of this study was to produce trait-improved cattle using the genome editing technology CRISPR–Cas9. Myostatin (MSTN) was selected as a target locus and synthetic mRNA of sgRNA and Cas9 was microinjected into bovine in vitro fertilized embryos. As a result, 17 healthy calves were born and 3 of these showed MSTN mutation rates of 10.5%, 45.4%, and 99.9%, respectively. Importantly, the offspring with the 99.9% MSTN mutation rate had biallelic mutation (-12bp) and a doubling muscle growth phenotype. In conclusion, we showed that the genome editing technology CRISPR–Cas9 can produce genetically modified calves with improved traits.
15 Apr 2021Submitted to Biotechnology Journal
16 Apr 2021Submission Checks Completed
16 Apr 2021Assigned to Editor
19 May 2021Reviewer(s) Assigned
01 Jun 2021Editorial Decision: Revise Minor
11 Jun 20211st Revision Received
16 Jun 2021Assigned to Editor
16 Jun 2021Submission Checks Completed
16 Jun 2021Reviewer(s) Assigned
29 Jun 2021Editorial Decision: Revise Minor
04 Jul 20212nd Revision Received
06 Jul 2021Assigned to Editor
06 Jul 2021Submission Checks Completed
06 Jul 2021Reviewer(s) Assigned
09 Jul 2021Editorial Decision: Accept